Ypsomed Holding

from Wikipedia, the free encyclopedia
Ypsomed Holding AG

logo
legal form Corporation
ISIN CH0019396990
founding 2003
Seat Burgdorf BE , Switzerland
management Simon Michel ( CEO )

Willy Michel (Chairman of the Board of Directors)

Number of employees 1600 (2019)
sales 453.7 million CHF (2019)
Branch Medical technology
Website www.ypsomed.ch

The Ypsomed Holding AG , based in Burgdorf is an internationally active Swiss Medical -Unternehmen. In 2019, Ypsomed employed around 1,600 people and generated a net profit of around 60 million Swiss francs on sales of 453.7 million Swiss francs. Ypsomed Holding is listed on the Swiss stock exchange SIX Swiss Exchange listed .

Field of activity

Ypsomed is a developer and manufacturer of injection systems for self-medication. The company manufactures customized injection pens and pen needles for diabetes , growth hormone or infertility therapies and other applications. Production takes place in Burgdorf and Solothurn, Switzerland.

Under the mylife Diabetescare brand , Ypsomed offers patients a range of self-made products or commercial products for the treatment of diabetes. Since 2010, Ypsomed has been the first provider in Europe to offer insulin pumps based on the patch pump principle from the American manufacturer Insulet . The partnership with Insulet ended on July 31, 2018.

history

Ypsomed was created in 2003 when the Burgdorf-based Disetronic group was split up . While the infusion area was sold to Roche Holding , the injection area was continued as an independent company under the name Ypsomed and was floated on the stock exchange in 2004 through an IPO . Simon Michel is CEO , Willy Michel is Chairman of the Board of Directors , founder of the company and main shareholder .

Web links

Individual evidence

  1. Ypsomed Annual Report 2018/19
  2. Ypsomed: 700 million dissolved in thin air in: Berner Zeitung of July 21, 2017